Large-scale regulatory reviews have not found evidence that these medications cause psychiatric harm, and many users report improved well-being as they lose weight
Review Article Abstract Introduction Retatrutide for Treatment of Obesity Retatrutide for Treatment of Type 2 Diabetes Effects of Retatrutide on Cardiovascular Risk Factors Safety of Retatrutide Effect of Retatrutide on Heart Rate Advantages of Retatrutide Limitations of Retatrutide Conclusions and Current Needs References Safety of Retatrutide In the 2 phase 2 trials, 16-17% discontinued retatrutide compared with 0-4% with placebo due to adverse effects (Table 1) [3,4]
Giorgio V et al (2013) Dimers of mitochondrial ATP synthase form the permeability transition pore
CJC-1295 and the FDA Bulk Drug Substance List CJC-1295 currently sits on the FDA's Category 2 list of bulk drug substances under evaluation for use in compounding [14]
Fujioka-Kobayashi M, Ota MS, Shimoda A, Nakahama KI, Akiyoshi K, Miyamoto Y, et al